Longer duration of anticoagulation therapy benefits cancer patients with isolated distal DVT

Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

RP-12146 by Rhizen Pharmaceuticals for Ovarian Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

June 19, 2024

Advancements in neoantigen vaccines offer hope for personalized cancer therapy

The saga of cancer treatment is marked by a relentless pursuit of effectiveness against a disease characterized by complexity and adaptability.

August 19, 2024

Neural patterns unravel distinctions between traumatic and sad memories in individuals with PTSD

Researchers investigate the neural patterns of patients with PTSD while listening to narratives that depicted their own memories.

November 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.